ADEKA CORPORATION FY2027 Q1 Earnings Report

Quick View

Executive Summary

The first quarter delivered strong results, with the core Chemicals and Life Sciences Businesses driving higher revenue and earnings, accompanied by margin improvement. Revenue was ¥117.04B (+15.2% YoY), Operating Income was ¥15.69B (+42.7%), Ordinary Income was ¥16.62B (+50.2%), and Net Income was ¥12.50B (+44.5%; of which ¥10.71B was attributable to owners of the parent, +47.8% YoY). The Operating Income margin improved to 13.4% from the previous year, with price and mix improvements and cost management supporting earnings growth.

Factors Affecting Performance

【Revenue】Revenue was ¥117.04B, representing a 15.2% YoY increase. By segment, the Chemicals Business posted the largest increase, at ¥62.87B (53.7% of total, +19.9%), followed by the Life Sciences Business at ¥31.09B (+14.6%). The Food Business recorded ¥21.47B (+4.3%), indicating slower growth and differing growth rates among segments.

【Profit and Loss】Operating Income was ¥15.69B (+42.7%). The gross margin increased to 30.3% from 28.5% in the previous year, while the SG&A ratio declined to 16.9% from 17.7%, resulting in earnings growth exceeding revenue growth. By segment, the Chemicals Business led company-wide earnings with ¥10.15B (+60.9%, 16.1% margin), while the Life Sciences Business also performed well, reporting ¥4.49B (+36.9%, 14.4% margin). In contrast, the Food Business posted ¥0.86B (▲21.7%, 4.0% margin), a decline in earnings, as delays in passing through price increases and responding to cost increases pressured profitability. Ordinary Income of ¥16.62B included contributions from non-operating income of ¥2.78B, including foreign exchange gains of ¥0.84B and interest income of ¥0.72B, among others; however, these were offset by non-operating expenses of ¥1.84B, including interest expenses of ¥0.87B, limiting the impact on Net Income. Extraordinary income and losses totaled a net ▲¥0.13B, indicating only a minor impact from temporary factors. Overall, the company achieved higher revenue and earnings, confirming structural margin improvement led by the Chemicals and Life Sciences Businesses.

Segment Analysis

The Chemicals Business was the largest earnings driver, accounting for approximately 60% of company-wide profit, with revenue of ¥62.87B (53.7% of total, +19.9%) and Operating Income of ¥10.15B (+60.9%, 16.1% margin). The Life Sciences Business expanded while maintaining a high margin, recording revenue of ¥31.09B (+14.6%) and Operating Income of ¥4.49B (+36.9%, 14.4% margin). The Food Business increased revenue to ¥21.47B (+4.3%), but Operating Income declined to ¥0.86B (▲21.7%, 4.0% margin), widening the profitability gap with other segments. The Other Businesses recorded revenue of ¥6.10B (+28.7%) but Operating Income of ¥0.21B (▲15.1%), with low margins persisting. Company-wide, margin disparities among segments have widened, confirming the high degree of dependence on the Chemicals and Life Sciences Businesses.

Key Financial Indicators

【Profitability】The Operating Income margin was 13.4%, the gross margin was 30.3%, and the Net Income margin, based on consolidated Net Income, was 10.7%; both the gross margin and Operating Income margin improved from the previous year. 【Cash Quality】The difference between Ordinary Income and Net Income was primarily attributable to income taxes of ¥3.99B and Net Income attributable to non-controlling interests of ¥1.79B. The impact of extraordinary income and losses was a minor ▲¥0.13B, and earnings quality was generally sound. However, inventories of ¥73.56B and accounts receivable of ¥116.27B represent substantial asset balances, and working-capital trends could affect cash conversion speed. 【Investment Efficiency】ROE was 3.3%, while Net Assets were ¥380.52B against Total Assets of ¥576.09B, indicating a moderate level of asset efficiency. 【Financial Soundness】The Equity Ratio was 66.1%, with Cash and Deposits of ¥98.61B, Long-Term Borrowings of ¥17.96B, and Bonds of ¥16.38B. Debt levels remained controlled and the financial foundation was strong.

Cash Flow Analysis

Although individual data from the statement of cash flows were not disclosed, funding trends can be inferred from changes in the balance sheet. Cash and Deposits increased to ¥98.61B from ¥96.54B in the previous-year period, confirming the accumulation of funds accompanying earnings growth. Meanwhile, inventories increased to ¥73.56B from ¥69.41B, indicating continued inventory buildup, including raw materials and work-in-process. Accounts receivable and notes receivable were ¥116.27B and remained broadly flat, suggesting that collections may not have kept pace with revenue growth. Long-Term Borrowings declined to ¥17.96B from ¥23.70B, indicating progress in debt reduction, while treasury stock decreased substantially to ▲¥4.50B from ▲¥19.00B, suggesting that greater flexibility in capital policy accounted for part of the use of funds. Overall, while earnings growth is generating funds, the increase in inventories warrants attention from the perspective of capital efficiency.

Quality of Earnings

The core source of recurring earnings was Operating Income of ¥15.69B. Non-operating income of ¥2.78B, approximately 2.4% of revenue, comprised interest income of ¥0.72B, dividend income of ¥0.39B, foreign exchange gains of ¥0.84B, and other items, indicating low dependence on specific temporary factors. Extraordinary income and losses consisted of a gain on the sale of fixed assets of ¥0.09B and extraordinary losses of ¥0.21B, including asset disposals, resulting in a minor net ▲¥0.13B and limited impact on Net Income. The difference between Ordinary Income of ¥16.62B and consolidated Net Income of ¥12.50B was primarily attributable to income taxes of ¥3.99B, and the effective tax rate was generally stable. Comprehensive Income of ¥20.36B exceeded Net Income, reflecting the addition of valuation differences on securities of ¥5.40B and foreign currency translation adjustments of ¥1.99B. In addition to current-period earnings, balance-sheet capital was strengthened through valuation gains. Overall, earnings were primarily generated by the core business, and earnings quality can be assessed as stable.

Earnings Forecast and Guidance

Q1 progress toward the full-year plan was 25.3% for Revenue (plan: ¥462.00B), 31.4% for Operating Income (plan: ¥50.00B), and 33.2% for Ordinary Income (plan: ¥50.00B), all exceeding the simple 25% run rate. In particular, progress on earnings exceeded progress on Revenue, indicating that the effects of price and mix improvements and cost management are emerging at a pace above the plan. During the quarter, the company revised its earnings and dividend forecasts. The full-year EPS forecast is ¥329.98, and the dividend forecast is ¥132.00.

Shareholder Returns

The company’s full-year dividend forecast is ¥132.00, implying a Payout Ratio of approximately 40.0% against the full-year EPS forecast of ¥329.98. Since the dividend in the previous-year period was ¥52, the full-year plan is expected to result in a dividend increase from the previous-year actual result. EPS for the first quarter was ¥110.10 (¥71.22 in the previous year, +54.6%), indicating that progress toward the full-year plan is ahead of schedule in terms of earnings. In addition, treasury stock declined substantially from ▲¥19.00B in the previous-year period to ▲¥4.50B, potentially expanding the scope for using treasury stock as a shareholder-return measure.

Risk Factors

1. Segment concentration risk: The Chemicals Business accounts for 53.7% of Revenue and approximately 65% of segment profit, meaning that fluctuations in raw-material markets and demand cycles could significantly affect company-wide performance.

2. Declining profitability in the Food Business: The Food Business’s Operating Income margin was 4.0%, with earnings declining by 21.7% YoY, substantially lagging other segments. Progress in passing through price increases and addressing costs remains a challenge.

3. Increase in working capital: Inventories increased to ¥73.56B from ¥69.41B in the previous year, while accounts receivable and notes receivable remained high at ¥116.27B. Trends in cash collection and inventory efficiency relative to earnings growth could affect cash conversion speed.

Industry Benchmark (Reference; Company Analysis)

Industry Benchmark (manufacturing)

Profitability and Returns

Both the company’s Operating Income margin and Net Income margin exceed the industry median, placing its profitability in the upper tier of the industry.

Growth and Capital Efficiency

The Revenue growth rate exceeds both the industry median and the upper bound of the upper range, demonstrating top-tier growth within the industry.

※Source: Company analysis

Key Points in the Earnings Results

1. The Chemicals and Life Sciences Businesses continued to achieve higher margins, and the Operating Income margin improved by 258bp to 13.4%. Positive operating leverage from the higher gross margin and lower SG&A ratio was confirmed, indicating a structural change that enabled earnings growth exceeding revenue growth.

2. Progress toward the full-year plan was 31.4% for Operating Income and 33.2% for Ordinary Income, exceeding the 25.3% progress for Revenue and confirming that earnings are ahead of schedule.

3. The decline in earnings in the Food Business, widening margin disparities among segments, and the increase in inventories are structural issues that warrant close monitoring in future earnings results.

Theoretical Share Price (Reference Value)

This is a mechanically calculated reference range based solely on publicly disclosed data using a residual income model (Ohlson-type model with an explicit five-year fade). It is not a forecast of the market share price or a recommendation of any specific investment action.

Sensitivity: ¥3,790–¥4,011 at a ±1% change in the cost of equity, and ¥3,897–¥3,899 at a ±0.1 change in ω.

Notes:

• As forecast ROE is below the cost of equity, the theoretical value is below book value per share.
• Net Assets as of the quarter-end are used; there is a timing difference from the full-year forecast.
• Because Net Assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Calculation model: Residual income model / Interest-rate reference month: 2026-07 / This value does not forecast or guarantee the future share price)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting professionals as necessary.

---End of Report---